This section contains the latest highlighted research for patients from ASCO medical journals, including the Journal of Clinical Oncology, as well as an archive of research highlights from previous ASCO scientific meetings (2011-2015). For the latest research highlights from more recent ASCO meetings, visit the Cancer.Net Blog or check out Cancer.Net’s audio podcasts and videos for patients.
To search this archive, use the drop-down menu below. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
In an ongoing study, researchers found that adding a new targeted therapy to chemotherapy controls non-Hodgkin lymphoma (NHL) growth for more than twice as long as only chemotherapy.
According to a recent small study, the drug daratumumab may work well as a treatment for multiple myeloma after other treatments have not worked.
A recent study shows that adding docetaxel (Docefrez, Taxotere) chemotherapy to the standard treatment of hormone therapy and radiation therapy helps men with high-risk, localized prostate cancer live longer.
A phase III clinical trial has shown that nivolumab (Opdivo) is an effective treatment option for people with non-squamous, non-small cell lung cancer (NSCLC).
Results from a small phase II study suggest that the PD-1 immunotherapy, pembrolizumab (Keytruda), works better when tumors have a large number of genetic changes or mutations.
In an early-stage study, nivolumab (Opdivo) has shown encouraging results as a treatment for advanced liver cancer. Liver cancer is the leading cause of cancer deaths worldwide, accounting for more than 600,000 deaths each year. People diagnosed with advanced liver cancer especially need new treatment options, as there is currently only one drug approved by the U.S. Food and Drug Administration (FDA).
Results from a phase I clinical trial show that pembrolizumab (Keytruda) is able to shrink head and neck cancer that has spread to other parts of the body or come back after treatment. These findings suggest that immunotherapy may fill a large unmet need for better treatments for recurrent and advanced head and neck cancer.
Two phase III Children’s Oncology Group studies found that using additional drugs with standard therapy lowered the chance that Wilms tumor with a specific genetic change returned after treatment. Wilms tumor is a rare type of cancer that begins in a child’s kidney. When it comes back after treatment, it is called a relapse or recurrence.
A large, ongoing study showed that men with advanced prostate cancer who received docetaxel (Docefrez, Taxotere) in addition to standard prostate cancer treatment lived longer than those who received only standard hormone therapy. The study also showed that including zoledronic acid (Zometa) along with docetaxel and standard hormone therapy did not offer additional benefits.
As part of an ongoing study, researchers found that a new immune-based treatment controlled the growth of multiple myeloma for longer than standard treatment. This new treatment, elotuzumab, works in two different ways to treat myeloma. It is able to directly target multiple myeloma cells and boost a part of the immune system that helps control the growth of cancer cells.